Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
ASCOGU 2026
Top resúmenes y presentaciones
Overall survival from the phase 2 trial of abiraterone,
olaparib, or abiraterone + olaparib in first-line metastatic
castration-resistant prostate cancer (mCRPC) with DNA
repair defects (BRCAAway).
16
Fifteen-year survival analysis from the ASCENDE-RT
randomized trial of external beam boost versus
brachytherapy boost in localized prostate cancer.
306
Final overall survival results from the EORTC 1333/PEACE-3 trial:
Enzalutamide with or without radium-223 in metastatic
castration-resistant prostate cancer.
15
SAVE: A multicenter randomized phase 2 trial of salvage
radiotherapy (SRT) with androgen-deprivation therapy
(ADT) versus apalutamide (Apa) for biochemical
progression after radical prostatectomy (RP).
364
Interim safety analysis of a randomized phase II trial
comparing pembrolizumab with radiation versus
pembrolizumab, olaparib, and radiation in localized high
risk prostate cancer.
362
ASCOGU 2026
PRÓSTATA
ASCOGU 2026
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
RC48G001: A phase 2 study of disitamab vedotin in
HER2-expressing previously treated advanced UC.
LBA631
Gemcitabine intravesical system (Gem-iDRS) in
combination with cetrelimab (CET) versus
chemoradiotherapy (CRT) in muscle-invasive bladder
cancer (MIBC): SunRISe-2 final results.
635
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus
pembrolizumab (pembro) for participants with muscle-
invasive bladder cancer (MIBC) who are eligible for cisplatin:
Randomized, open-label, phase 3 KEYNOTE-B15 study.
LBA630
Urinary tumor DNA (utDNA) and circulating tumor DNA
(ctDNA) in patients (pts) with muscle-invasive bladder
cancer (MIBC) who received perioperative durvalumab (D)
in NIAGARA.
636
Pathological outcomes and disease-free survival (DFS) in
KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj)
enfortumab vedotin (EV) plus pembrolizumab (pembro) in
participants (pts) with muscle-invasive bladder cancer
(MIBC) who are cisplatin-ineligible.
638
ASCOGU 2026
UROTELIAL
ASCOGU 2026
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib
(cabo) for advanced renal cell carcinoma (RCC) after
anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011
study
LBA417
Adjuvant pembrolizumab plus belzutifan versus
pembrolizumab for clear cell renal cell carcinoma (ccRCC):
The randomized phase 3 LITESPARK-022 study
LBA418
A randomized phase II trial of cytoreductive stereotactic
hypofractionated radiotherapy with ipilimumab/nivolumab for
metastatic kidney cancer.
416
Ascending dose escalation of belzutifan plus palbociclib
for previously treated advanced clear cell renal cell
carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.
423
Cirulating KIM-1 and ctDNA as pronostic markers in
oligometastasic clear cell carcinoma (ccRCC): The
K-KOMPASS model
537
ASCOGU 2026
RENAL
ASCOGU 2026
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Patient-reported outcomes in resected renal cell
carcinoma: Active monitoring vs. durvalumab and
tremelimumab in the RAMPART trial.
420